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Amyloid f32-microglobulin is modified with imidazolone, a novel
advanced glycation end product, in dialysis-related amyloidosis
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Amyloid 32-microglobulin is modified with imidazolone, a novel ad-
vanced glycation end product, in dialysis-related amyloidosis. We have
recently demonstrated by immunohistochemistiy that amyloid p2-micro-
globulin (2m) is modified with advanced glycation end products (AGEs)
in dialysis-related amyloidosis (DRA). To further investigate the role of
the Maillard reaction in the pathogenesis of DRA, we produced a
monoclonal antibody to imidazolone, a novel AGE, and a reaction
product of arginine and 3-dcoxyglucosone (3-DG) which was accumulated
in uremic serum. Then we determined the localization of imidazolone in
the amyloid tissues by immunohistochemistry using the antibody. The
connective tissues in carpal tunnel and ligamentum flavum were obtained
from six patients with carpal tunnel syndrome and two patients with
destructive spondyloarthropathy. Imidazolone was localized to all the
2m-positive amyloid deposits in these patients. Western blotting using
the antibody demonstrated that j32m extracted from the synovium amyloid
of hemodialysis patients was modified with imidazolone. Further, f32m
isolated from the blood ultrafiltrate of hemodialyzed patients was also
modified with imidazolone. In vitro incubation of j32m with 3-DG pro-
duced imidazolone-modified 2m. In conclusion, amyloid tissue 2m is
modified with imidazolone in patients with DRA. 3-DG accumulating in
uremic serum may be involved in the modification of J32m with imida-
zolone.
Dialysis-related amyloidosis (DRA) is a serious complication in
patients maintained on long-term dialysis [1]. Carpal tunnel
syndrome (CTS), cystic lesions of long bones, particularly in the
femoral and humeral heads, destructive spondyloarthropathy
(DSA), and diffuse arthritis and periarthritis of the scapulo-
humeral region are seen with increasing frequency as a conse-
quence of amyloid deposition in these patients. The major com-
ponent of arnyloid has been demonstrated to he /32-microglobulin
(2m) [2—6].
f32rn isolated from the amyloid deposits in patients with DRA
has been demonstrated to be modified with advanced glycation
end products (AGEs) [71 AGE-/32m may be involved in the
pathogenesis of DRA by stimulating the chemotaxis of mono-
cytes, the secretion of IL-lp and TNF- from macrophages, and
the subsequent synthesis of collagenase in synovial cells [8].
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We demonstrated that AGE was localized to amyloid deposits
in patients with DRA by immunohistochemistry using a monoclo-
nal anti-AGE antibody (AG-b) [9], the epitope of which was
N-(carboxymethyl)lysine [10]. To clarify the mechanism of AGE
modification of j32m-amyloid, we studied the effects of 3-deoxy-
glucosonc (3-deoxy-D-erythro-hexos-2-ulose, 3-DG) on the AGE
modification of 132m, and quantitated the serum levels of 3-DG in
dialysis patients [11, 12]. 3-DG is produced from Amadori prod-
ucts as an intermediate of the Maillard reaction, and is a potent
stimulator for the formation of AGEs [13—16] (Fig. 1). Then we
found that 3-DG accumulating in uremic serum may be involved
in the AGE modification of 2m-amyloid [12].
Several compounds such as N-(carboxymethyl)lysine [171, pyr-
raline [18], pentosidine [19], crosslines [20] and imidazolones [21,
22] have been proposed as the structures of AGEs. Although
N-(carboxymcthyl)lysine, pyrraline, and imidazolone compounds
do not have color or fluorescence, and do not crosslink proteins,
these compounds are usually included in the category of AGEs
because they are also the advanced products of Maillard reaction.
The AGE modification of long-lived proteins has been postulated
to contribute to the development of pathologies associated with
diabetes mellitus [23—261, aging [27], DRA [7—10, 121 and Alzhei-
mer's disease [28—301. The in vivo presence of AGEs has been
demonstrated in hemoglobin [26], lens crystalline [27], f32m [7—10,
121, -amyloid peptide and tau protein [28—30].
Recently, imidazolone compounds have been isolated from the
incubation solution of 3-DG and an arginine derivative [21, 22]. It
has been reported that 3-DG first attacks arginirle residues in
proteins and then reacts with the lysine residues under physiolog-
ical conditions at 37°C and pH 7.4 [13, 14]. Thus, 3-DG reacts with
guanidino groups of arginine residues in the proteins, forming
imidazolone modification of the arginine residues. We produced
several clones of monoclonal anti-AGE antibodies, and found
that one of the antibody reacted specifically with imidazolone.
To further study the role of the Maillard reaction in the
pathogenesis of DRA, we examined if amyloid 132m is modified
with imidazolone, by immunohistochemistry and immunochemis-
try using the anti-imidazolone antibody. This study first demon-
strates the in vivo presence of imidazolonc, a novel AGE, in
amyloid /32m.
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Fig. 1. Nonenzymatic synthesis of 3-deoxyglucosone (3-DG) and advanced glycation end products (A GEs) in the Maillard reaction.
Table 1. Profile of patients with DRA and immunohistochemical detection of imidazolone in amyloid of synovium
Patient Age Sex
Duration
of HD
years
Cause of
renal
failure
Source
of
tissue
—
Serum
creatinine
mg/dl
Serum ,m
pg/mi
Staining of amyloid. — in tissue
Congo red 2m Imidazolone
K.N. 54 M 20.8 CGN r-CT 12.7 34.7 +++ +++ ++
Y.S. 56 F 12.6 CGN 1-CT 7.8 27.5 ++ +++ +
SM. 46 M 17.1 CGN 1-CT 12.4 30.3 +++ +++ ++
KS. 49 F 15.9 CGN r-CT 11.3 35.6 +++ +++ ++
TI. 49 M 23.2 CGN I-CT 9.1 24.1 +++ +++ ++
KY. 52 M 18.0 CGN 1-CT 11.1 38.5 +++ +++ ++
T.N. 54 M 23.0 CGN LF(L3/4) 11.3 21.3 +++ +++ +++
Y.E. 51 M 21.0 CGN LF(L3/4) 12.4 26.5 ++ ++ +
Abbreviations are: M, male; F, female; CGN, chronic glomerulonephritis; r, right; I, left; CT, carpal tunnel; LF, ligamentum fiavum (L, lumbar
vertebrae).
Methods
Patients and preparation of amyloid tissues and plasma 132m
Samples of carpal tunnel connective tissues and lumbar liga-
mentum flavum tissues were obtained during surgical operation
from six hemodialyzed patients with CTS and two patients with
DSA, respectively (Table I). All the patients were dialyzed against
a bicarbonate dialysate (Kindaly AF-2: Na 140 mEq/litcr, K 2.0
mEq/liter, Ca2 3.0 mEq/liter, Mg2 1.0 mEq/liter, Cl 110
mEq/liter, CH3COO 8 mEq/liter, HCO 30 mEq/liter, glucose
10(1 mgldl; Fuso Co., Osaka, Japan). The dialyzers used were
PS-1.9UW (polysulfone; Fresenius AG, Homburg, Germany) for
a patient KN, FB-130A (cellulose triacetale; Nipro Co., Osaka,
Japan) for patients YS and KS, BK-2.IP (polymcthylmethacry-
late; Toray Co., Tokyo, Japan) for SM, PS-i.6UW (polysulfone,
Fresenius AG) for Ti, BK-I .6P (polymethylmethacrylate; Toray
Co.) for KY, FLX-I5GW (polymer alloy; Nikiso Co., Tokyo,
Japan) for TN, and BK-1.6U (polymethylmethacrylate; Toray
Co.) for YE. The tissue specimens were divided into thin sections.
These sections were then fixed in 20% phosphate-buffered form-
aldehyde, dehydrated in a graded series of ethanol, and embedded
in paraffin. Amyloid deposits were identified by Congo red
staining.
For isolation of plasma 2m, samples of blood ultrafiltrate were
obtained during isolated ultrafiltration using /32m-permeable
membrane dialyzers from a 60-year-old female diabetic hemodi-
alysis (HD) patient without CTS on HD for 9 years, and a
60-year-old male non-diabetic HD patient with CTS on HD for 24
years. The ultrafiltrate samples (about 500 ml) were desalted by
dialysis against distilled water at 4°C. After lyophilization the
sample solutions were loaded onto DEAE-Sepharose Fast Flow
ion exchange chromatography (Pharmacia) using linear gradient
elution from 10 m phosphate buffer, p1-I 7.0, to 10 m phosphate
buffer, pH 7.0, containing 0.3 M NaC1. 2m fraction was then
isolated by Sephadex G-75 Superfine (Pharmacia) gel permeation
chromatography using 127 fflM ammonium bicarbonate.
For isolation of plasma albumin, blood ultrafiltrate sample was
also obtained during isolated ultrafiltration using a 2m-perme-
able membrane dialyzer from a 60-year-old male non-diabetic HD
patient without CTS on HI) for 8 years. The ultrafiltrate sample
was desalted by dialysis against distilled water at 4°C. After
lyophilization the sample solution was loaded onto Sephadex
G-50 Superfine (Pharmacia) gel permeation chromatography, and
NH2
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0
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then albumin fraction was separated using 127 mrvi ammonium
bicarbonate.
To study if imidazolone modification is involved in the other
forms of amyloid, kidneys containing amyloid deposits were
obtained by autopsy from four patients with AL amyloidosis
(65-year-old male with primary amyloidosis, 54-year-old male with
primary amyloidosis, 59-year-old female with multiple myeloma of
lg A A type, and a 66-year-old female with multiple myeloma of lg
G,< type), and three patients with AA amyloidosis (74-year-old
female with rheumatoid arthritis, 58-year-old female with rheu-
matoid arthritis, and a 60-year-old female with systemic lupus
crythematosus). The tissue specimens were fixed, dehydrated and
embedded as described above.
in vitro preparation of A GE-modified proteins and lysine analog
AGE-modified keyhole limpet hemocyanin (AGE-KLH),
AGE-modified human serum albumin (AGE-HSA), AGE-modi-
fied bovine serum albumin (AGE-BSA), AGE-modified f32m and
AGE-modified lysine were produced by incubating KLH (20
g/liter), HSA (100 g/liter), BSA (100 g/liter), [32m (100 mg/liter) or
lysine (1 M) (all from Sigma Chemical Company, St. Louis, MO,
USA), respectively, at 37°C for one month (HSA, BSA, 2m) or
three months (KLH) with I vi glucose in 0.2 M phosphate buffer,
pH 7.4, containing 0.02% NaN3. 3-DG (1 M) was incubated with
2 vi N-p-tosyl-L-lysine-methyl ester (Tos-Lys-Me; Sigma Chem-
ical Company) in 0.2 vi phosphate buffer, pH 7.4, at 37°C for two
months, to examine the reactivity of anti-imidazolone antibody
with the incubated solution.
in vitro preparation of imidazolone compounds
3-DG (0.2 M) was incubated with 0.1 M NvbenzoylLarginine
(Benz-Arg-amide; Nakarai Chemical Co., Kyoto, Japan) in 0.1 M
sodium phosphate buffer, pH 7.4, at 50°C for 132 hours as
reported in previous literature [12, 131. As shown in Figure 2, two
imidazolone compounds, 2-(4-benzoylamino-5-pentamide)-ami-
no-5-(2,3,4-trihydroxybutyl)-4(5 H)-imidazolone (imidazolone A)
and 2-(4-benzoylamino-5-pentamide)-amino-5-(2,3,4-trihydroxy-
butyl)-4-imidazolone (imidazolone B) were purified from the
incubated solution by high-performance liquid chromatography.
Production and characterization of monoclonal anti-imidazolone
antibody
Monoclonal anti-AGE antibodies were produced by immuniz-
ing mice with AGE-KLH as described in detail in the previous
paper [9j. The antibodies in the culture medium were cloned by
sandwich enzyme-linked immunosorbent assay (ELISA) using
anti-mouse igU antihodyeoated plate, AGE-HSA, and peroxi-
dase-labeled anti-HSA antibody, and then two monoclonal clones
of anti-AGE antibodies (AG-i and AG-Il)) were produced.
Recently, the epitope of AG-lU has been found to be N°-
(carhoxymethyl)lysine 1101.
The reactivity of the anti-AGE antibody (AG-I) with reduced
AGE-USA, AGE-BSA or AGE-1m was studied using the com-
petitive ELISA. Figure 3 shows the reactivity of the monoclonal
anti-AGE antibody (AG-i) with the AGE-modified proteins.
That the anti-AGE antibody was unreactive with early Amadori
glycation products, was confirmed by the observation that sodium
borohydride reduction, which alters the Amadori product epitope,
did not affect the reactivity of the antibody to AGE-HSA once
formed. The anti-AGE antibody did not react with eaproyl
pyrraline. Hydrolysis of AGE-HSA and AGE-BSA with 6 M HCI
at 110°C for 24 hours markedly reduced their reactivity with the
anti-AGE antibody, suggesting that the anti-AGE antibody does
not react with pentosidine, which is stable under acid hydrolysis.
Since the anti-AGE antibody did not react with AGE-modified
lysine (the incubation solution of lysine and glucose), the major
product of which was W-(carboxymethyl)lysine, the antibody does
not recognize N-(carboxymethyl)Iysine. Thus, the anti-AGE an-
tibody was demonstrated not to react with Amadori products, or
well-known AGE structures like pyrraline, pentosidine or N-
(carboxymethyl)lysine.
The epitope of the anti-AGE antibody (AG-I) was found to be
imidazolone, since the antibody reacted with imidazolone A,
imidazolone B, and the incubated solution of 3-DG and Benz-
Arg-amide, but did not react with 3DG or Benz-Arg-amide (Fig.
4). The antibody did not react with the incubation solution of
3-DG and Tos-Lys-Me, the major product of which was N- (car-
boxymethyl)lysine.
immunohistochemical detection of imidazolone and 132m in
amyloid
Imidazolone and 2m in the amyloid deposits were studied
using the peroxidase-antiperoxidase (PAP) method with mono-
clonal anti-imidazolone antibody (AG-i) and anti-human 2m
antibody as reported by us [9].
Control samples to which the primary antibody had not been
applied, were processed simultaneously. The same concentration
of primary anti-AGE antibody was incubated with imidazolone at
37°C for 90 minutes. After centrifuging the mixture at 10,000 g for
30 minutes, the supernatant was used as the primary antibody
solution followed by the usual PAP method.
In these experiments, the slides were read by a pathologist in a
blinded fashion, and scored on a semiquantitative scale (zero to
+ + +) according to the degree of positive staining.
Extraction of f32m from amyloid tissues of HD patients
2m fraction was extracted from DRA tissues as described
previously [12].
Sodium dodecyl sulfate-polyaciylamide gel electrophoresis
(SDS-PA GE) and Western blotting
SDS-PAGE and Western blotting were performed as described
previously [12].
in vitro incubation of (32m with 3-DG
2m (1 mg/nil) was incubated (I) alone, (2) with 10 mvi 3-DG,
and (3) with 1 vi glucose, in 0.2 vi phosphate buffer, pH 7.4, at
37°C for four weeks. The incubated solution was used for ELISA
using anti-im idazolone antibody (AG-i).
Competitive ELISA fhr imidazolone
Sample solution (25 /Ll) or standard AGE-HSA (0 to 200
mg/liter) was incubated at room temperature for one hour in
AGE-HSA (0.01 g/litcr) coated microplate with PBS containing
0.25% BSA (50 ,ul), and peroxidase-conjugated anti-AGE anti-
body (AG-i). After washing four times with PBS, o-phenylenedi-
amine (100 tl) was added to the mieroplate. Reaction was
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stopped by adding 1.6 vi I-12S04 (100 jd), and absorption at 492 deposits that stained with Congo red, also reacted with anti-2m
nm was measured using 620 nm as control. antibody, indicating that the amyloid deposits were composed of
132m, Immunostaining with anti-imidazolone antibody showed theResults . .
presence of imidazolone localized to those areas stained with
Immunohistochemical detection of imidazolone in 13gm amyloid Congo red and anti-2m antibody.
tissues Figure 6 demonstrates amyloid deposition in lumbar ligamen-
Figure 5 demonstrates the presence of amyloid deposits in turn flavum from a patient with DSA (T.N.). The amyloid deposits
carpal tunnel synovium from a patient with CTS (K.N.). Amyloid were composed of f32m, since the amyloid deposits stained with
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Competitor, rig/mI
Fig. 3. Competitive EL ISA demonstrating the specificity of monoclonal
anti -imidazolone antibody (AG-]). The anti-imidazolone antibody reacted
with AGE-HSA (0), reduced AGE-HSA (S), AGE-BSA (U), and
AGE-132m (Lx), but did not react with HSA (A), BSA (X) or f3,m (Li).
Thus, the antibody recognizes a common epitope of AGE. B (Bound)
stands for the fractions of labeled antibody bound to immobilized antigen
after an addition of a sample solution, and B0 (bound at zero concentra-
tion) stands for the fraction of labeled antibody bound to immobilized
antigen without adding any sample solution. Thus, B/B0 represenis the
ratio of absorhance of a sample solution (B) to that of a blank solution
(B0) in which no sample was added.
Congo red and anti-f32m antibody. Immunostaining with anti-
imidazolone antibody demonstrated the localization of imida-
zolone corresponding to those areas stained with both Congo red
and anti-/32m antibody. Therefore, immunostaining with anti-
imidazolone antibody demonstrated the presence of imidazolone
in the /32m-amyloid deposits and, more notably, in the infiltrating
cells surrounding these amyloid deposits. However, imidazolone
in the cells did not react with the anti-/32m antibody.
Table I summarizes the immunohistochemical detection of
imidazolone in the 2m-amyloid tissues from six patients with
CTS and two patients with DSA. All the /32m-amyloid tissues
showed positive staining with anti-imidazolone antibody, demon-
strating the localization of imidazolone in the f32m-amyloid tis-
sues. Control experiment, in which the primary anti-imidazolone
antibody was not used, and absorption experiment in which the
primary anti-imidazolone antibody was preincubated with imida-
zolone, revealed an absence of staining in the amyloid deposits.
Imniunostaining with the anti-imidazolone antibody demon-
strated that imidazolone was not localized to Congo-red-positive
amyloid deposits in kidneys obtained from four patients with AL
amyloidosis and three patients with AA amyloidosis.
Immunochemical detection of amyloid f37m and plasma 13,m
modified with imidazolone
Figure 7 shows the photographs of Western blotting using
anti-2m antibody and anti-imidazolone antibody (AG-I) after
separation by SDS-PAGE of amyloid f32m extracted from /32m-
amyloid tissues and plasma 2m isolated from blood ultrafiltrate
samples of hemodiafyzed patients. The amyloid 2m monomer
and dimer were demonstrated to be modified with imidazolone by
positive immunostaining with the anti-imidazolone antibody. The
plasma J32m in the ultrafiltrate was also demonstrated to be
Competitor, ig/ml
Fig. 4. Competitive ELISA demonstrating the specificity of monoclonal
anti -imidazolone antibody (AG-I). The anti-imidazolone antibody reacted
with imidazolone A, imidazolone B, and the solution of 3-DC incubated
with Benz-Arg-amide, but did not react with 3-DC, Benz-Arg-amide or
the solution of 3-DG incubated with Tos-Lys-Me (N'-p-tosyl-L-lysine-
methyl ester). Thus, the anti-imidazolone antibody reacted specifically
with the imidazolone compounds. Symbols are: (0) AGE-HSA; (•)
3DG + Benz-Arg-amide; (A) Imidazolone A; (Li) Tmidazolooe B; ()
Benz-Arg-amide; (X) 3DG; (•) 3DG + Tos-Lys-Me.
modified with imidazolone. Absorption experiment in which the
primary anti-imidazolone antibody was preincubated with imida-
zolone, showed negative immunostaining of the amyloid and
plasma 2m. However, plasma f32m is not specifically susceptible
to imidazolone modification, because albumin fraction isolated
from the ultrafiltrate was also modified with imidazolone by
positive immunostaining with the anti-imidazolone antibody after
separation by SDS-PAGE.
Modification of f32m with imidazolone by incubating with 3-DG
Figure 8 demonstrates that /32m incubated with 3-DG (10 mM)
showed much higher reactivity against anti-imidazolone antibody
than that incubated with glucose (I M). Thus, incubation of f32m
with 3-DG produced imidazolone-modified 132m as observed in
the amyloid tissues and plasma of hemodialyzed patients.
Discussion
Our results demonstrate that amyloid 2m in DRA is modified
with imidazolone, a novel AGE, and that imidazolone-modified
2m is also detectable in the plasma of 1-ID patients. The
association of imidazolone may be specific for 32m-amyloid,
because imidazolone was not located in the other forms of
amyloid (AL or AA). The imidazolone-modified 2m may be
produced by reacting /32m with 3-DG accumulating in uremic
serum as demonstrated in in vitro incubation of 132m with 3-DG.
Imidazolone was also noted in the infiltrating cells, presumably
macrophages, surrounding these tissues. However, the cells did
not react with anti-f32m antibody. The staining pattern with
anti-imidazolone antibody was similar to those with anti-ACE
antibody (AG-b), the epitope of which was identified as N-
(carboxymethyl)lysine [10]. The lack of f32m epitope in the
imidazolone-positive cells suggests that imidazolone-modified
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Fig. 5. Photornicrographs of arnyloid tissues in carpal tunnel obtained from
K.N. A. Congo red staining (x50). B. Staining with anti-2m antibody
(PAP method, x50). C. Staining with anti.imidazolone antibody (AG-I)
at 10 tg/ml (PAP method, X50). Immunostaining with anti-imidazolone
antibody demonstrated the localization of imidazolone in the ,m-amyloid
deposits. Publication of this figure in color was made possible by a grant
from Maruko Pharmaceutical Co., Ltd., Aichi, Japan.
2m is degraded to its imidazolone-modified peptide or imida-
zolone itself by the cells after its endoeytosis. Otherwise, intracel-
lular immunostaining with anti-imidazolonc antibody could indi-
cate that intracellular proteins are nonspecifIcally modified with
imidazolone.
Fig. 6. Photomicrographs of amyloid tissues in ligarnenturnflavum obtained
franz TN. A. Congo red staining (X50). B. Staining with anti-2m antibody
(PAP method, ><50). C. Staining with anti-imidazolone antibody (AG-i)
at 10 jzg/ml (PAP method, X50). Immunostaining with anti-imidazolonc
antibody demonstrated the localization of imidazolone in the ,m-amyloid
deposits and, more notably, in the infiltrating cells (C) surrounding these
amyloid deposits. However, the cells did not react with the anti-,m
antibody (B). Publication ot this figure in color was made possible by a
grant from Maruko Pharmaceutical Co., Ltd., Aichi, Japan.
Imidazolone may be a useful biomarker for Maillard reaction
damage of tissue proteins. AGEs have been reported to be
biologically active on macrophages [31, 321. However, it has not
yet been reported that imidazolone is biologically active on
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Fig. 7. Western blotting using anti-J3,m antibody and anti-imidazolone antibody (AG-i) after separation by SDS-PAGE of amyloid f32m extracted from
,m-amyloid tissues and plasma J32m isolated from blood ultrafiltrate samples of hemodialyzed patients. The amyloid 2m and the plasma 132m were
demonstrated to be modified with imidazolone. Lane 1, amyloid 2m; Lane 2, amyloid 132m; Lane 3, amyloid 2m; Lane 4, 132m; Lane 5, plasma 2m;
Lane 6, plasma 2m.
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Fig. 8. Competitive ELISA demonstrating the reactivity of monoclonal
anti-imidazolone antibody (AG-i) with 2m incubated alone, 2m incubated
with 3-DG (iO mM) or f32m incubated with glucose (1 M), in 0.2 MphOsphate
buffer (pH 7.4) at 37°C for 4 weeks. The anti-imidazolone antibody reacted
most strongly with 32m incubated with 3-DG, very weakly with j32m
incubated with glucose, but not at all with j32m incubated alone. Thus,
incubation of ,m with 3-DG produced imidazolone-modified 2m as
detected in the amyloid tissues and plasma of hemodialyzed patients.
Symbols are: (0) ,m (1 mg/mI); () (7m glucose (1 M); () 2m +
3-DG (10 mM).
macrophages. Since serum levels of 3-DG are elevated in HD
patients (11, 121, and reactions of proteins with 3-DG are known
to produce AGEs such as pyrraline [33], pentosidine [34], N'-
(carhoxymethyl)lysine [10, 121 and imidazolone [21, 221, these
AGE structures are to he present in the 2m extracted from DRA
tissues. In fact, we demonstrated the modification of 2m-amyloid
with N-(carhoxymethyl)lysine [10, 12] and imidazolone.
The presence of imidazolone-modified 132m in the plasma of
HD patients may suggest that imidazolone-modified f32m may
deposit in connective tissues forming 2m-amyloid. However, the
positive immunostaining with anti-imidazolone antibody does not
necessarily indicate that the major component of plasma 132m is
modified with imidazolone, but more probably, only a trace
component of plasma 132m may be modified with imidazolone. We
do not consider that /32m is specifically susceptible to modification
with AGEs like imidazolone as compared to the other plasma
proteins, because albumin isolated from the blood ultrafiltrate of
a HD patient was also modified with imidazolone. Further, we
found that the major component of f32m isolated from f32m-
amyloid was a native form of 132m [10]. A probable mechanism to
explain the formation of imidazolone-modified 32m-amyloid is to
be modified with imidazolone after deposition of j32m as amyloid.
Once amyloid is formed, it is difficult to degrade. Then it may
react with 3-DG and become modified with imidazolone even in
normoglycemia after a long time period of deposition as /32m
amyloid. Further, a concomitant generation of oxygen radicals,
which occurs in HD patients [351, may enhance aggregation of
amyloid j32m. Thus, a uremic state in which 3-DG is accumulated
accelerates the AGE modification of f32m amyloid. The lack of the
stimulating factor for AGE modification in the other forms of
amyloid (AA and AL) may explain that both imidazolone and
W-(carboxymethyl)lysine [9, 101 were not located in these forms
of amyloid.
We found that the serum levels of 3-DG were markedly
increased not only in diabetic patients [36] but also in non-diabetic
uremic patients [11, 12]. 3-DG first attacks arginine residues in
proteins and then reacts with the lysine residues under physiologic
conditions [21, 22]. In fact, the f32m incubated with 3-DG showed
a strong reactivity against anti-imidazolone antibody as demon-
strated by ELISA. The observation that the 2m incubated with
glucose showed weak reactivity against anti-imidazolonc antibody
can be explained by production of a small amount of 3-DG during
the in vitro incubation of glucose with 7m. 3-DG reacts with a
guanidino group of arginine residues in f32m, forming an imida-
zolone modification of the arginine residues. We propose the
hypothesis that 3-DG accumulating in uremic blood promotes the
modification of 2m with AGEs including imidazolone mainly
after deposition of /32m as an amyloid.
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